흡입기용 용액 시장 규모, 점유율, 동향 분석 보고서 : 흡입기 유형별, 약물 종류별, 용도별, 유통 채널별, 지역별, 부문별 예측(2026-2033년)

Inhaler Solution Market Summary

The global inhaler solution market size was estimated at USD 31.42 billion in 2025 and is projected to reach USD 49.79 billion by 2033, growing at a CAGR of 5.9% from 2026 to 2033. This growth is primarily driven by the rising prevalence of respiratory disorders such as asthma and chronic obstructive pulmonary disease, increasing exposure to air pollution and tobacco smoke, and growing awareness of early diagnosis and long-term disease management.

The growing global prevalence of chronic respiratory diseases, particularly asthma and Chronic Obstructive Pulmonary Disease (COPD), continues to be a primary driver for the inhaler solutions market. According to the World Health Organization (WHO), asthma affects over 262 million people worldwide, and COPD remains the third leading cause of death globally, responsible for millions of lives lost each year. This rising disease burden is not only a global health challenge but also a significant factor in driving the demand for inhaler therapies. Environmental factors, such as increasing urbanization and air pollution, exacerbate these respiratory conditions, creating a more urgent need for inhaler-based treatments. In Southeast Asia, where rapid industrialization and pollution are prevalent, the prevalence of asthma and COPD is increasing, as highlighted by a BMC Public Health study in February 2024. The study shows a clear correlation between environmental pollution and worsening respiratory diseases in the region.

These respiratory diseases require ongoing management and are typically treated with inhalers that deliver medication directly to the lungs, making them the preferred method of treatment. As global air quality deteriorates, particularly in densely populated urban areas, the number of patients requiring inhalers grows. In addition, the increasing number of elderly populations, who are more susceptible to chronic respiratory diseases, adds further strain on healthcare systems, pushing up the demand for effective inhaler solutions. According to the WHO, the global aging population is expected to rise dramatically, leading to a corresponding increase in the number of patients suffering from respiratory diseases. The increase in disease prevalence directly correlates with greater market demand, as more patients require chronic disease management and effective symptom control.

Improved access to essential medicines and health products is becoming a significant factor supporting the growth of the inhaler solution market, especially in low and middle income countries (LMICs). In July 2025, a report by the Office of the United Nations High Commissioner for Human Rights (OHCHR) underlines that access to medicines remains far from universal: as of 2025, about two billion people worldwide still lack consistent access to essential medicines and health products. The report emphasizes that improving availability, affordability, and distribution of essential medicines including those for chronic diseases such as asthma and COPD is critical.

More specifically, a 2023 study published in the journal related to global health equity noted that although many respiratory medicines including inhaled therapies are listed on the World Health Organization (WHO) Essential Medicines List (EML), their availability and affordability in LMICs remain inconsistent. This indicates that in many underserved regions, prior constraints on access to inhalation therapy are starting to ease, driven by policy emphasis on essential medicines, improvements in supply chain and distribution frameworks, and increased public health prioritization of non-communicable diseases (NCDs).

As access improves both in terms of presence of inhaler drugs/devices in national essential medicines lists and their distribution through public health infrastructure, a larger portion of the population becomes eligible for and capable of using inhaler therapies for asthma and COPD. This expands the addressable market for inhaler devices beyond traditional high income geographies and supports greater market penetration in emerging regions. Such expansion, when combined with rising disease burden and device diversification, strengthens the long term growth potential for inhaler solution providers globally.

Global Inhaler Solution Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global inhaler solution market report based on inhaler type, drug class, application, distribution channel, and region:

• Inhaler Type Outlook (Revenue, USD Million, 2021 - 2033)
• Pressurized Metered-Dose Inhalers (pMDIs)
• Dry-Powder Inhalers (DPIs)
• Soft Mist Inhalers (SMIs)
• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
• ICS
• LAMA/LABA
• SAMA/SABA
• Combination Therapies
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Cystic Fibrosis
• Others
• Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
• Retail Pharmacies
• Institutional / Hospital Pharmacies
  • Public
  • Private
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Malaysia
  • Indonesia
  • Myanmar
  • Laos
  • Cambodia
  • Vietnam
  • Yemen
  • Pakistan
• Latin America
  • Brazil
  • Argentina
  • Chile
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Inhaler Type
  • 1.2.2. Drug Class
  • 1.2.3. Application
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Inhaler Solution Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Inhaler Solution Market: Inhaler Type Business Analysis

• 4.1. Inhaler Type Market Share, 2025 & 2033
• 4.2. Inhaler Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Inhaler Type, 2021 to 2033 (USD Million)
• 4.4. Pressurized Metered-Dose Inhalers (pMDIs)
  • 4.4.1. Pressurized Metered-Dose Inhalers (pMDIs) Market, 2021 - 2033 (USD Million)
• 4.5. Dry-Powder Inhalers (DPIs)
  • 4.5.1. Dry-Powder Inhalers (DPIs) Market, 2021 - 2033 (USD Million)
• 4.6. Soft Mist Inhalers (SMIs)
  • 4.6.1. Soft Mist Inhalers (SMIs) Market, 2021 - 2033 (USD Million)

Chapter 5. Inhaler Solution Market: Drug Class Business Analysis

• 5.1. Drug Class Market Share, 2025 & 2033
• 5.2. Drug Class Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
• 5.4. ICS
  • 5.4.1. ICS Market, 2021 - 2033 (USD Million)
• 5.5. LAMA/LABA
  • 5.5.1. LAMA/LABA Market, 2021 - 2033 (USD Million)
• 5.6. SAMA/SABA
  • 5.6.1. SAMA/SABA Market, 2021 - 2033 (USD Million)
• 5.7. Combination Therapies
  • 5.7.1. Combination Therapies Market, 2021 - 2033 (USD Million)

Chapter 6. Inhaler Solution Market: Application Business Analysis

• 6.1. Application Market Share, 2025 & 2033
• 6.2. Application Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by application, 2021 to 2033 (USD Million)
• 6.4. Asthma
  • 6.4.1. Asthma Market, 2021 - 2033 (USD Million)
• 6.5. Chronic Obstructive Pulmonary Disease (COPD)
  • 6.5.1. Chronic Obstructive Pulmonary Disease (COPD) Market, 2021 - 2033 (USD Million)
• 6.6. Cystic Fibrosis
  • 6.6.1. Cystic Fibrosis Market, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Inhaler Solution Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2025 & 2033
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
• 7.4. Retail Pharmacies
  • 7.4.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
• 7.5. Institutional / Hospital Pharmacies
  • 7.5.1. Institutional / Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.5.2. Public
    • 7.5.2.1. Public Market, 2021 - 2033 (USD Million)
  • 7.5.3. Private
    • 7.5.3.1. Private Market, 2021 - 2033 (USD Million)
• 7.6. Online Pharmacies
  • 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 8. Inhaler Solution Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 8.4. North America
  • 8.4.1. North America Inhaler Solution Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Application Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Application Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. U.S. Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Application Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Application Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. Uk Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Application Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Application Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Application Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Application Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Application Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Application Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Application Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Application Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Application Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Application Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Application Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Application Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Application Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.8. Malaysia
    • 8.6.8.1. Key Country Dynamics
    • 8.6.8.2. Application Disease Prevalence
    • 8.6.8.3. Regulatory Framework
    • 8.6.8.4. Reimbursement Framework
    • 8.6.8.5. Malaysia Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.9. Indonesia
    • 8.6.9.1. Key Country Dynamics
    • 8.6.9.2. Application Disease Prevalence
    • 8.6.9.3. Regulatory Framework
    • 8.6.9.4. Reimbursement Framework
    • 8.6.9.5. Indonesia Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.10. Myanmar
    • 8.6.10.1. Key Country Dynamics
    • 8.6.10.2. Application Disease Prevalence
    • 8.6.10.3. Regulatory Framework
    • 8.6.10.4. Reimbursement Framework
    • 8.6.10.5. Myanmar Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.11. Laos
    • 8.6.11.1. Key Country Dynamics
    • 8.6.11.2. Application Disease Prevalence
    • 8.6.11.3. Regulatory Framework
    • 8.6.11.4. Reimbursement Framework
    • 8.6.11.5. Laos Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.12. Cambodia
    • 8.6.12.1. Key Country Dynamics
    • 8.6.12.2. Application Disease Prevalence
    • 8.6.12.3. Regulatory Framework
    • 8.6.12.4. Reimbursement Framework
    • 8.6.12.5. Cambodia Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.13. Vietnam
    • 8.6.13.1. Key Country Dynamics
    • 8.6.13.2. Application Disease Prevalence
    • 8.6.13.3. Regulatory Framework
    • 8.6.13.4. Reimbursement Framework
    • 8.6.13.5. Vietnam Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.14. Yemen
    • 8.6.14.1. Key Country Dynamics
    • 8.6.14.2. Application Disease Prevalence
    • 8.6.14.3. Regulatory Framework
    • 8.6.14.4. Reimbursement Framework
    • 8.6.14.5. Yemen Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.15. Pakistan
    • 8.6.15.1. Key Country Dynamics
    • 8.6.15.2. Application Disease Prevalence
    • 8.6.15.3. Regulatory Framework
    • 8.6.15.4. Reimbursement Framework
    • 8.6.15.5. Pakistan Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Application Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Brazil Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Application Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. Argentina Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Chile
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Application Disease Prevalence
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Reimbursement Framework
    • 8.7.4.5. Chile Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Application Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Application Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Application Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Application Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Inhaler Solution Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Boehringer Ingelheim
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. GSK
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. AstraZeneca
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Novartis
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Chiesi Farmaceutici
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Mundipharma
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Orion Corporation
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Aptar Pharma
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Vectura Group
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Kindeva Drug Delivery
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives